Streetbeat News

Products Services

PROK

ProKidney shares are trading lower following an operational update and progress report on European and U.S. clinical trials for its CKD therapy, rilparencel. Jefferies maintained a Buy rating but lowered the price target from $15 to $6.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 7:19 pm

LLY

Eli Lilly's Alzheimer's drug has received a unanimous 11-0 vote from an FDA panel. The panel will next review the safety and potential limits of the drug.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 7:14 pm

AAPL

Apple's WWDC 2024 event has concluded, showcasing new products and software updates. Key announcements included the latest iPhone model, advancements in AI integration, and updates to the iOS operating system.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 6:45 pm

AAPL

Apple has announced that it will integrate ChatGPT into iOS 18, iPadOS 18, and macOS Sequoia later this year. This announcement was made at the WWDC24 event.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 6:43 pm

AAPL

GOOGL

The article discusses the performance of shares of Google and Apple, with mentions of other AI models. It highlights the importance of monitoring these tech giants as they continue to innovate in the AI space.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 6:42 pm

ATVI

MSFT

Call of Duty: Black Ops 6 will require a constant internet connection for all game modes on consoles, a first for the series. This was revealed during Microsoft's Xbox Games Showcase and confirmed by Activision. The game will also be available on Xbox Game Pass at launch.

Portfolio Pulse from Franca Quarneti

June 10, 2024 | 6:39 pm

AAPL

MSFT

Apple has announced a partnership with OpenAI to integrate ChatGPT into its products. This collaboration aims to enhance user experience by leveraging advanced AI capabilities.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 6:38 pm

ARQT

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) presented new long-term data on roflumilast cream 0.15% for treating mild to moderate atopic dermatitis in adults and children aged 6 and older. The study showed continued improvements in symptoms, including itch, over 56 weeks, with 66.2% of participants achieving a 75% improvement in Eczema Area and Severity Index (EASI-75). The cream was well-tolerated with no new safety signals.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 6:32 pm

G

TraceLink has partnered with Genpact to enhance digital supply chain solutions for the healthcare and life sciences sectors. The collaboration aims to leverage advanced technology and AI to improve cost, service, predictability, and resiliency across supply chains.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 6:31 pm

INDV

Indivior has initiated a Phase 2 study for INDV-2000, a non-opioid treatment for Opioid Use Disorder. The study will assess the safety and efficacy of INDV-2000 over three months in treatment-seeking individuals.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 6:31 pm